Construction and Comprehensive Prognostic Analysis of a lncRNA-miRNA-mRNA Regulatory Network and Tumor Immune Cell Infiltration in Colorectal Cancer.

bioinformatics analysis ceRNA network colorectal cancer infiltrating immune cells prognostic model

Journal

Frontiers in genetics
ISSN: 1664-8021
Titre abrégé: Front Genet
Pays: Switzerland
ID NLM: 101560621

Informations de publication

Date de publication:
2021
Historique:
received: 12 01 2021
accepted: 11 06 2021
entrez: 19 7 2021
pubmed: 20 7 2021
medline: 20 7 2021
Statut: epublish

Résumé

Colorectal cancer (CRC) is a malignant tumor with high morbidity and mortality worldwide. Recent studies have shown that long noncoding RNAs (lncRNAs) play an important role in almost all human tumors, including CRC. Competitive endogenous RNA (ceRNA) regulatory networks have become hot topics in cancer research. Tumor-infiltrating immune cells (TICs) have also been reported to be closely related to the survival and prognosis of CRC patients. In this study, we used the lncRNA-miRNA-mRNA regulatory network combined with tumor immune cell infiltration to predict the survival and prognosis of 598 CRC patients. First, we downloaded the lncRNA, mRNA, and miRNA transcriptome data of CRC patients from The Cancer Genome Atlas (TCGA) database and identified differentially expressed genes through "limma" package of R software. The ceRNA regulatory network was established by using the "GDCRNATools" R package. Then, univariate Cox analysis and least absolute shrinkage and selection operator analysis were performed to identify the optimal prognostic network nodes, including SRPX, UST, H19, SNHG7, hsa-miR-29b-3p, and TTYH3. Next, we analyzed the differences in 22 types of TICs between 58 normal subjects and 206 CRC patients and included memory CD4 T cells, dendritic cells and neutrophils in the construction of a prognostic model. Finally, we identified the relationship between the ceRNA prognostic model and the infiltrating immune cell prognostic model. In conclusion, we constructed two prognostic models that provide insights on the prognosis and treatment strategy of CRC.

Identifiants

pubmed: 34276767
doi: 10.3389/fgene.2021.652601
pmc: PMC8281064
doi:

Types de publication

Journal Article

Langues

eng

Pagination

652601

Informations de copyright

Copyright © 2021 Guo, Liang, Wang, Cheng, Qin, Zhang and Wang.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Hematol Oncol. 2018 Jul 3;11(1):89
pubmed: 29970122
Cell Death Dis. 2018 Jun 18;9(7):722
pubmed: 29915311
Front Pharmacol. 2019 Jun 06;10:588
pubmed: 31244652
Sci Rep. 2019 Oct 22;9(1):15122
pubmed: 31641220
J Immunol Res. 2019 Feb 13;2019:3046379
pubmed: 30944831
Cancers (Basel). 2019 Oct 19;11(10):
pubmed: 31635093
Pigment Cell Melanoma Res. 2015 Sep;28(5):490-500
pubmed: 25818762
Cancer Res. 2017 Nov 1;77(21):e108-e110
pubmed: 29092952
Onco Targets Ther. 2019 Dec 31;12:11609-11621
pubmed: 32021241
Cancer Sci. 2019 May;110(5):1564-1572
pubmed: 30861269
Cell Rep. 2018 Oct 9;25(2):513-522.e3
pubmed: 30304689
Oncol Lett. 2018 Sep;16(3):3365-3372
pubmed: 30127936
Sci Rep. 2017 Aug 11;7(1):7882
pubmed: 28801584
Mol Cancer. 2018 Nov 30;17(1):169
pubmed: 30501625
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Eur Rev Med Pharmacol Sci. 2019 Feb;23(4):1476-1486
pubmed: 30840269
Cancers (Basel). 2020 Mar 28;12(4):
pubmed: 32231042
Int J Mol Sci. 2019 Nov 16;20(22):
pubmed: 31744051
Cancer Treat Rev. 2018 Apr;65:22-32
pubmed: 29502037
Front Oncol. 2021 Mar 12;11:618967
pubmed: 33777763
BMC Cancer. 2020 Oct 21;20(1):1022
pubmed: 33087099
Int J Cancer. 2020 May 15;146(10):2901-2912
pubmed: 31633800
BMC Cancer. 2021 Mar 9;21(1):255
pubmed: 33750326
Nat Genet. 2013 Aug;45(8):860-7
pubmed: 23797736
Med Sci Monit. 2019 Sep 02;25:6581-6586
pubmed: 31475695
Oncol Lett. 2020 Aug;20(2):1452-1461
pubmed: 32724388
Front Cell Dev Biol. 2021 Feb 05;9:622459
pubmed: 33614651
Oncol Rep. 2019 Dec;42(6):2706-2715
pubmed: 31638245
Exp Biol Med (Maywood). 2011 May 1;236(5):567-79
pubmed: 21486861
Mol Cells. 2018 May 31;41(5):423-435
pubmed: 29754471
J Immunol. 2011 Jun 15;186(12):6905-13
pubmed: 21551365
Biomed Pharmacother. 2017 Nov;95:55-61
pubmed: 28826097
Mol Cancer. 2019 Oct 16;18(1):143
pubmed: 31619268
Front Physiol. 2018 Apr 10;9:321
pubmed: 29692736
Cancer Cell Int. 2019 Apr 11;19:90
pubmed: 31007608
Cell Oncol (Dordr). 2019 Dec;42(6):757-768
pubmed: 31359293
Front Immunol. 2019 Sep 24;10:2278
pubmed: 31616440

Auteurs

Xiong Guo (X)

Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Xiaolong Liang (X)

Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Yujun Wang (Y)

Department of Pathology, Daping Hospital, Army Military Medical University, Chongqing, China.

Anqi Cheng (A)

Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Chuan Qin (C)

Department of Gastrointestinal Surgery, Three Gorges Hospital, Chongqing University, Chongqing, China.

Han Zhang (H)

Department of Digestive Oncology, Three Gorges Hospital, Chongqing University, Chongqing, China.

Ziwei Wang (Z)

Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Classifications MeSH